Optimer Pharmaceuticals said its lead drug candidate for the treatment of Clostridium difficile, a drug-resistant "superbug" known to wreak havoc on a patient's gastrointestinal tract, outperformed the only FDA-approved drug to treat the infection in a recent study, sending shares up more than 90 percent in morning trading Nov...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99